Chemokine- and cytokine-induced expression of endothelin 1 and endothelin-converting enzyme 1 in endothelial cells

被引:53
作者
Molet, S
Furukawa, K
Maghazechi, A
Hamid, Q
Giaid, A
机构
[1] Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada
[2] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada
[3] Univ Oslo, Dept Anat, N-0316 Oslo, Norway
关键词
endothelin; endothelin-converting enzyme 1; endothelial cells; Northern blot; messenger RNA; chemokines; cytokines; radioimmunoassay; human;
D O I
10.1016/S0091-6749(00)90084-8
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Endothelin 1 (ET-1) is a product of endothelial and many other cell types that possesses a wide range of actions, including vasoconstriction, bronchoconstriction, and mitogenic activity on smooth muscle cells and fibroblasts. ET-1 release and expression is induced in several disease conditions associated with inflammation and cellular injury. Objective: The purpose of this study is to determine the effects of alpha-chemokines (IL-8 and melanoma growth-stimulating activator), beta-chemokines (monocyte chemotactic protein 1, macrophage inflammatory protein 1 alpha [MIP-1 alpha], MIP-1 beta, and RANTES), and proinflammatory cytokines (IL-1 beta, TNF-alpha, and IFN-gamma) on the expression of both ET-1 and endothelin-converting enzyme 1 (ECE-1) by human umbilical vein endothelial cells. Methods: Subconfluent monolayers of human umbilical vein endothelial cells were incubated with each chemokine individually for 24 hours or with a mixture (cytomix) of TNP-alpha, IL-1 beta, and IFN-gamma for 6 and 24 hours. Results: Incubation with the alpha-chemokines melanoma growth-stimulating activity and IL-8 did not significantly increase ET-1 and ECE-1 messenger (m)RNA expression and had no effect on ET-1 release. Monocyte chemotactic protein 1 exerted the most potent increase in ET-1 and ECE-1 mRNA and ET-1 release among all chemokines studied (P < .05), MTP-1 alpha and RANTES exerted a moderate, but significant, increase on the ET system (P < .05). The cytomix resulted in a significant increase in ET-1 and ECE-1 mRNA expression (P < .05). Conclusion: These data demonstrate that, like cytokines, chemokines can induce endothelial ET-1 and ECE-1 in vitro and suggest a possible role for these inflammatory mediators in the induction of the ET system in inflammatory and vascular diseases.
引用
收藏
页码:333 / 338
页数:6
相关论文
共 33 条
  • [1] Chemokines as mediators of allergic inflammation
    Bacon, KB
    Schall, TJ
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1996, 109 (02) : 97 - 109
  • [2] GENOMIC SEQUENCING
    CHURCH, GM
    GILBERT, W
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (07): : 1991 - 1995
  • [3] CORDER R, 1995, J CARDIOVASC PHARM, V26, pS56
  • [4] T-CELLS AND EOSINOPHILS IN THE PATHOGENESIS OF ASTHMA
    CORRIGAN, CJ
    KAY, AB
    [J]. IMMUNOLOGY TODAY, 1992, 13 (12): : 501 - 507
  • [5] ENDOTHELIN PEPTIDES - BIOLOGICAL ACTIONS AND PATHOPHYSIOLOGICAL SIGNIFICANCE IN THE LUNG
    FILEP, JG
    [J]. LIFE SCIENCES, 1993, 52 (02) : 119 - 133
  • [6] Co-expression of endothelin-1 and endothelin-converting enzyme-1 in patients with chronic rhinitis
    Furukawa, K
    Saleh, D
    Bayan, F
    Emoto, N
    Kaw, S
    Yanagisawa, M
    Giaid, A
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1996, 14 (03) : 248 - 253
  • [7] ENDOTHELIN-1 STIMULATES MONOCYTES IN-VITRO TO RELEASE CHEMOTACTIC ACTIVITY IDENTIFIED AS INTERLEUKIN-8 AND MONOCYTE CHEMOTACTIC PROTEIN-1
    HELSET, E
    SILDNES, T
    KONOPSKI, ZS
    [J]. MEDIATORS OF INFLAMMATION, 1994, 3 (02) : 155 - 160
  • [8] HELSET E, 1994, CIRC SHOCK, V44, P201
  • [9] THE HUMAN ENDOTHELIN FAMILY - 3 STRUCTURALLY AND PHARMACOLOGICALLY DISTINCT ISOPEPTIDES PREDICTED BY 3 SEPARATE GENES
    INOUE, A
    YANAGISAWA, M
    KIMURA, S
    KASUYA, Y
    MIYAUCHI, T
    GOTO, K
    MASAKI, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) : 2863 - 2867
  • [10] JIANG YL, 1992, J IMMUNOL, V148, P2423